{
    "nct_id": "NCT04557449",
    "official_title": "A PHASE 1/2A STUDY EVALUATING THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND ANTI-TUMOR ACTIVITY OF PF-07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS",
    "inclusion_criteria": "Healthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Part 1D: participants who have had a gastrectomy or have dietary or other restrictions that preclude a 10 hour overnight fast or consumption of the high fat, high calorie meal\n* Part 2B: prior neoadjuvant or adjuvant treatment with a non-steroidal aromatase inhibitor with disease recurrence while on or within 12 months of completing treatment. Prior treatment with any CDK4/6 inhibitor\n* Part 2C: prior treatment with any CDK inhibitor, fulvestrant, everolimus, or any agent whose mechanism of action is to inhibit the PI3K-mTOR pathway\n* Known active uncontrolled or symptomatic Central Nervous System (CNS) metastases carcinomatous meningitis, or leptomeningeal disease\n* Other active malignancy within 3 years prior to randomization, except for adequately treated basal cell or squamous cell skin cancer, or carcinoma in situ\n* Major surgery or radiation within 4 weeks prior to study intervention\n* Last anti-cancer treatment within 2 weeks prior to study intervention\n* Participation in other studies involving investigational drug(s) within 4 weeks prior to study entry\n* Pregnant or breastfeeding female participant\n* Active inflammatory gastrointestinal (GI) disease, known diverticular disease or previous gastric resection or lap band surgery including impairment of gastrointestinal function or GI disease",
    "miscellaneous_criteria": "Inclusion Criteria\n\n* Part 1: Breast Cancer (BC)\n\n  * Refractory Hormone Receptor Positive (HR+), Human Epidermal Growth Factor Receptor 2 Negative (HER2-) BC\n  * Part 1A/Part 1D/Part1E also include: Refractory HR-positive/HER2-positive BC\n* Part 1: Tumors other than BC (Part 1A/Part 1D/Part 1E): NSCLC, prostate, CRC, liposarcoma, or tumors with previously confirmed CDK4 or CCND1 amplification according to local standard tests\n* Part 1F: prostate cancer\n* Part 2A, 2B, 2C and 2E:\n\n  * HR-positive/HER2-negative BC\n  * Patients who are either postmenopausal women or pre/peri-menopausal (Part 2C only)\n* Part 1D: metastatic castration resistant prostate cancer\n* Lesion:\n\n  * Part 1: evaluable lesion (including skin or bone lesion only)\n  * Part 2A, 2B, 2C and 2E: measurable lesion per RECIST v1.1\n  * Part 2D: Participants with evaluable disease as per PCWG3; participants with bone metastases only are allowed. Participants with biochemical recurrence only are excluded.\n* Prior systemic Treatment\n\n  * Part 1: HR-positive/HER2-negative BC\n\n    * At least 1 line of SOC, including CD4/6 inhibitor therapy for advanced or metastatic disease, or if CDK4/6 inhibitors are not considered appropriate in the opinion of the investigator\n    * At least 1 line of anti-endocrine in countries without CDK4/6 inhibitor approval or reimbursement, for advanced or metastatic disease\n    * HR-positive/HER2-positive BC (Parts 1A/1D/1E): at least 1 prior treatment of approved HER2 targeting therapy\n    * Tumors other than BC (Parts 1A/1D/1E/1F): tumor that is resistant to at least 2 lines of SOC for advanced or recurrent disease or for which no standard therapy is available\n  * Part 2A and 2E: participants must have received at least 1 line of standard of care (including prior CDK4/6i) for advanced/metastatic disease; Prior chemo is allowed; Prior fulvestrant, mTOR and/or PI3K inhibitors are allowed\n  * Part 2B: participants who have not received any prior systemic anti-cancer therapies for advanced/metastatic BC\n  * Part 2C:\n\n    * Progressed during treatment or within 12 months of completion of adjuvant therapy with an aromatase inhibitor if postmenopausal, or tamoxifen if pre or perimenopausal, or\n    * Progressed while on or within 1 month after the endo the prior aromatase inhibitor therapy for advanced/metastatic BC if postmenopausal or prior endocrine treatment for advanced/metastatic BC if pre or perimenopausal\n    * One previous line of chemotherapy for advanced/metastatic disease is allowed in addition to endocrine therapy\n  * Part 2D:\n\n    * Received prior abiraterone; enzalutamide and CDK4i naive\n    * 0-1 line of chemotherapy is allowed General Inclusion Criteria\n* All participants must be refractory to or intolerant of existing therapies known to provide clinical benefit for their condition.\n* Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0 or 1\n* Adequate renal, liver, and bone marrow function"
}